A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
about
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report.Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacyImmune Checkpoints as Therapeutic Targets in Autoimmunity
P2860
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
@en
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
@nl
type
label
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
@en
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
@nl
prefLabel
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
@en
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
@nl
P2093
P2860
P1433
P1476
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
@en
P2093
Changyu Wang
Christopher A Lazarski
Eugene Hwang
Juanjuan Su
Martin Devenport
Mingyue Liu
Peiying Ye
P2860
P2888
P304
P356
10.1038/S41422-018-0011-0
P50
P577
2018-02-22T00:00:00Z